Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes

Cytarabine resistance characterizes relapsed and refractory acute myelogenous leukemia (AML). Restoration of cytarabine sensitivity can potentially improve treatment outcome in this setting. Acquired hypermethylation of gene promoters and associated silencing of gene expression has been implicated i...

Full description

Saved in:
Bibliographic Details
Main Authors: BORTHAKUR, GAUTAM, HUANG, XUELIN, KANTARJIAN, HAGOP, FADERL, STEFAN, RAVANDI, FARHAD, FERRAJOLI, ALESSANDRA, TORMA, RITVA, MORRIS, GAIL, BERRY, DONALD, ISSA, JEAN-PIERRE
Format: Artigo
Language:Inglês
Published: 2010
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2876330/
https://ncbi.nlm.nih.gov/pubmed/20017599
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428190903318329
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items